Remarkable progress has been made in the development of new therapies for cancer,
dramatically changing the landscape of treatment approaches for several malignancies and …

Numerous protein kinases encoded in the genome have become attractive targets for the
treatment of different types of cancer. As of January 2020, a total of 52 small-molecule …

Background: Sodium–glucose cotransporter-2 (SGLT2) inhibitors have been shown to
decrease the adverse cardiac events and risks of cardiovascular mortality among patients …

Animal models are 78% accurate in determining whether drugs will alter contractility of the
human heart. To evaluate the suitability of human-induced pluripotent stem cell-derived …

Targeted oncology therapies have revolutionized cancer treatment over the last decade and
have resulted in improved prognosis for many patients. This advance has emanated from …

Kinase inhibitors have transformed the treatment of many cancers and are showing the
same promise for other indications including inflammatory diseases. This class of drugs is …

Tyrosine kinase inhibitors (TKIs) are associated with cardiac toxicity, which may be caused
by mitochondrial toxicity. The underlying mechanisms are currently unclear and require …

Although the epidermal growth factor receptor 2 (ErbB2) and Notch1 signaling pathways
have both significant roles in regulating cardiac biology, their interplay in the heart remains …

Drug discovery and development continues to be a challenge to the pharmaceutical industry
despite great advances in cell and molecular biology that allow for the design of better …

Sorafenib (Sor), a novel multi-target anticancer drug also induces severe toxicity in heart,
while the mechanism of its cardiotoxicity remains to be fully elucidated. Dysregulation of …